A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)
Public ClinicalTrials.gov record NCT05384626. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors (ALKOVE-1)
Study identification
- NCT ID
- NCT05384626
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Nuvalent Inc.
- Industry
- Enrollment
- 840 participants
Conditions and interventions
Interventions
- Neladalkib (NVL-655) Drug
Drug
Eligibility (public fields only)
- Age range
- 12 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 8, 2022
- Primary completion
- Nov 30, 2027
- Completion
- Dec 31, 2027
- Last update posted
- Oct 29, 2025
2022 – 2028
United States locations
- U.S. sites
- 21
- U.S. states
- 17
- U.S. cities
- 19
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of California Irvine Medical Center | Orange | California | 92868 | Recruiting |
| University of California, Davis Comprehensive Cancer Center | Sacramento | California | 95817 | Recruiting |
| Stanford Cancer Institute | Stanford | California | 94305 | Recruiting |
| University of Colorado Cancer Center | Aurora | Colorado | 80045 | Recruiting |
| Georgetown University Medical Center | Washington D.C. | District of Columbia | 20007 | Recruiting |
| University of Miami; Sylvester Cancer Center | Miami | Florida | 33136 | Recruiting |
| Winship Cancer Institute, Emory University | Atlanta | Georgia | 30322 | Recruiting |
| University of Chicago Medical Center | Chicago | Illinois | 60637 | Recruiting |
| John Hopkins University | Baltimore | Maryland | 21224 | Recruiting |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Henry Ford Cancer Institute | Detroit | Michigan | 48202 | Recruiting |
| Washington University School of Medicine Siteman Cancer Center | St Louis | Missouri | 63310 | Recruiting |
| Laura & Isaac Perlmutter Cancer Center at NYU Langone Health | New York | New York | 10016 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Duke University Medical Center | Durham | North Carolina | 27705 | Recruiting |
| OSU Brain & Spine Hospital | Columbus | Ohio | 43210 | Recruiting |
| University of Pennsylvania, Abramson Cancer Center | Philadelphia | Pennsylvania | 19104 | Recruiting |
| Sarah Cannon | Nashville | Tennessee | 37203 | Recruiting |
| MD Anderson Cancer Center | Houston | Texas | 77030 | Active, not recruiting |
| Fred Hutchinson Cancer Center | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 53 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05384626, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 29, 2025 · Synced May 11, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05384626 live on ClinicalTrials.gov.